Background

One in four older adults admitted to hospital are taking medications with an anticholinergic effect. This anticholinergic effect has been linked with a higher chance of harmful effects including delirium (confusion) and suffering a fall. Older adults are particularly vulnerable to these harmful effects. Suffering a fall or delirium during a hospital stay can have a devastating impact on an older person.

If we can identify, based on a person’s anticholinergic medication and clinical characteristics, who is at risk of these harmful effects, we can intervene to reduce their risk. The anticholinergic medication index is a clinical tool which has been developed using data from GP practices to identify which anticholinergic medications are more likely to lead to harmful effects.

Aims & Objectives

Aims & Objectives:

  • To determine whether the anticholinergic medication index can identify those individuals who are more likely to develop delirium or suffer a fall during a hospital stay.
  • To determine whether combining the anticholinergic medication index with other clinical information about a person leads to a better prediction of who is more likely to suffer a harmful effect in hospital.

Methods

We will use anonymised routinely collected hospital data from hospitals in the West Midlands and Bradford to evaluate how well the ACMI predicts in-hospital falls and delirium. We will review the existing literature to identify clinical characteristics that indicate a person is at higher risk of suffering in-hospital falls and delirium. We will then combine these clinical characteristics with the ACMI to see if the predictive ability is improved.

Finally, we will use data from a different set of hospitals to see if we get similar results to ensure the revised tool can be used nationally.

Partners & Collaborators

Investigators
Dr Matthew Knight
Prof Andrew Clegg
Dr Kate Best
Dr Oliver Todd

Collaborators:

University of Leeds

Timescales

07/08/2024 – 06/08/2027

Funding agency

Health Data Research UK: Medicines in Acute and Chronic Care Driver Programme

Further information

For further information contact Dr Matthew Knight